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Abstract
Background: Stratifying dengue risk within endemic countries is crucial for allocating limited control interventions.
Current methods of monitoring dengue transmission intensity rely on potentially inaccurate incidence estimates.
We investigated whether incidence or alternate metrics obtained from standard, or laboratory, surveillance
operations represent accurate surrogate indicators of the burden of dengue and can be used to monitor the force
of infection (FOI) across urban centres.
Methods: Among those who reported and resided in 13 cities across the Philippines, we collected epidemiological
data from all dengue case reports between 2014 and 2017 (N 80,043) and additional laboratory data from a cross-
section of sampled case reports (N 11,906) between 2014 and 2018. At the city level, we estimated the aggregated
annual FOI from age-accumulated IgG among the non-dengue reporting population using catalytic modelling. We
compared city-aggregated FOI estimates to aggregated incidence and the mean age of clinically and laboratory
diagnosed dengue cases using Pearson’s Correlation coefficient and generated predicted FOI estimates using
regression modelling.
Results: We observed spatial heterogeneity in the dengue average annual FOI across sampled cities, ranging from
0.054 [0.036–0.081] to 0.249 [0.223–0.279]. Compared to FOI estimates, the mean age of primary dengue infections
had the strongest association (ρ −0.848, p value<0.001) followed by the mean age of those reporting with warning
signs (ρ −0.642, p value 0.018). Using regression modelling, we estimated the predicted annual dengue FOI across
urban centres from the age of those reporting with primary infections and revealed prominent spatio-temporal
heterogeneity in transmission intensity.
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Conclusions: We show the mean age of those reporting with their first dengue infection or those reporting with
warning signs of dengue represent superior indicators of the dengue FOI compared to crude incidence across
urban centres. Our work provides a framework for national dengue surveillance to routinely monitor transmission
and target control interventions to populations most in need.
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Background
Dengue is a mosquito-borne viral disease in which indi-
viduals can suffer up to four times during their lifetime
due to the existence of four distinct serotypes (DENV1-
4). A primary (first) dengue infection with any serotype
induces IgG antibodies that offer protection against
homologous serotype infections yet allow subsequent
post-primary (secondary, tertiary or quaternary) infec-
tions with heterologous serotypes [1, 2]. Severe dengue
disease is associated with, though not limited to, second-
ary infections due to pre-existing, cross-reactive, IgG
antibodies that do not protect against infection, but ra-
ther facilitate antibody-dependent enhancement of viral
replication [3]. Without specific therapeutics or a widely
available vaccine, costly vector control interventions re-
main the predominant method of dengue control [4]. To
appropriately deploy these limited interventions, dengue
national surveillance operations in endemic countries
must accurately monitor force of infection (FOI) over
space and time.
In countries where dengue is a notifiable disease, na-
tional surveillance efforts typically collate dengue case
reports over specified time periods to generate incidence
estimates. This readily available data can be used to in-
form the deployment of limited control interventions,
thus maximise their impacts. However, case reporting is
heavily influenced by disease awareness and variable
healthcare infrastructure, which can distort generated
measures [5]. Alternatively, population-based surveys or
cohort studies including seroprevalence [6] and entomo-
logical surveys [7] can provide more reliable estimates of
disease risk within their operational setting and are con-
sidered the gold standards for measuring long-term
average transmission intensity. Yet, surveys are labour-
intensive and difficult to conduct routinely over large
geographical areas, so have limited use for routine sur-
veillance proposes.
Recently, age-stratified incidence measures of case re-
ports have been proposed as more suitable indicators of
transmission intensity [5, 8, 9]. In areas of high transmis-
sion, the burden of disease is believed to disproportion-
ately impact younger individuals compared to lower
transmission areas where individuals likely report with
dengue later in life due to the accumulation of immunity
over time. This approach helps counter bias introduced
by variable health care infrastructures and disease
awareness although suffers two major caveats. First, case
reporting is dependent on a variety of different diagnos-
tics between and within endemic countries. Surveillance
operations rely on non-specific diagnostics or clinical
manifestations for notifying dengue [10]. Consequently,
other co-endemic febrile infections, which manifest simi-
larly to dengue and are common among children may
prompt more younger individuals to seek care and be
misdiagnosed as dengue infections [11, 12]. Second,
among those reporting with true dengue infections, rou-
tinely used diagnostics are currently unable to distin-
guish those experiencing primary or post-primary
infections [1]. Therefore, the age of case reports may be
influenced by spatio-temporal imbalances in reported
dengue immune status. Stratifying age estimates among
those truly experiencing their primary infection may
help to overcome these limitations.
In the Philippines, dengue has become a major con-
tributor to mortality and morbidity over the past 50
years with all four serotypes believed to be endemic
across urban centres [13]. Existing dengue surveillance
operations consist of collating all reported dengue infec-
tions and surveying a subset for subsequent laboratory
analysis. The serum is collected from sampled case re-
ports for molecular and serological testing to allow
spatio-temporal monitoring of dengue serotypes. Prior
to this study, we utilised laboratory data from surveyed
dengue patients to develop an algorithm that accurately
determines individual primary or post-primary (second-
ary, tertiary or quaternary) immune status [14]. Despite
this, it remains unknown how surveillance metrics de-
rived from this algorithm can best be used to routinely
characterise the FOI. Previous studies have demon-
strated that the FOI can be reasonably estimated from
age-stratified incidence rates [5, 9]. However, it remains
unknown if other, easily computed, surveillance metrics
represent surrogate indicators of the FOI. Here, we in-
vestigated whether laboratory/non-laboratory surveil-
lance metrics correlate with the FOI according to age-
seroprevalence and be used to routinely predict the bur-
den of dengue across urban centres.
Methods
Data collection
Dengue is a notifiable disease among all disease report-
ing units (DRUs) across the Philippines and is recorded
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in line with The Philippine Integrated Disease Surveil-
lance and Response (PIDSR) manual and WHO criteria
[15]. Basic epidemiological data are collected from sus-
pected dengue patients, including age, sex, date of symp-
tom onset, date of reporting, patient/DRU address
(barangay, municipality, province, region), symptoms
and outcome. According to WHO criteria, dengue
symptoms are classified among patients as those with
acute febrile illness coupled with either no warning signs
of dengue (abdominal pain, persistent vomiting, fluid ac-
cumulation, mucosal bleeding, lethargy and/or live en-
largement) or severe dengue (severe plasma leakage,
bleeding and/or organ impairment). All case reports
were collated by the Philippine Epidemiological Bureau
(Department of Health).
In addition to collated case reports, established labora-
tory surveillance operations performed by the Research
Institute for Tropical Medicine (RITM—the research
arm of the Department of Health) orchestrate annual
cross-sectional surveys of dengue case reports across the
country for further laboratory analysis. Participating
DRUs, both sentinel and non-sentinel, collect single
serum samples and basic epidemiological information
(according to PIDSR criteria) from consenting, reporting
dengue patients. Sentinel DRUs, including major hospi-
tals, randomly select five case report samples per week.
Non-sentinel DRUs comprising of any health facility
across the Philippines that experiences a marked in-
crease in suspected dengue case reporting according to
PIDSR criteria also collected samples from case reports.
For the purposes of this study, surveyed case report data
were provided between 2014 and 2018 (N 20,666).
During the study period, a total of 13 cities across the
Philippines routinely provided serum samples from den-
gue patients who reported and resided in the same city
(N 11,906) (Fig. 1) (Additional file 1). In these same cit-
ies between 2014 and 2017, a total of 80,043 case reports
reported and lived in these corresponding cities. The
population age structures of these cities according to the
Philippine 2015 census (Philippine Statistics Authority)
are shown in Additional file 2.
Laboratory procedures
Serum samples were stored at −80°C at the RITM before
molecular and serological assay. Serum samples were
assayed using a serotype-specific, fourplex real-time re-
verse transcriptase PCR nucleic acid detection assay as
described in [16]. Briefly, serotype-specific RNA is de-
tected and amplified yielding a critical threshold (Ct)
value that categorises samples as DENV1/2/3 or 4 posi-
tive (Ct<36) or DENV negative (Ct>36). In addition,
samples were assayed for anti-DENV IgM and IgG using
Panbio® capture ELISA kits (Cat No: 01PE10/01PE20,
Alere, Brisbane, Australia) in accordance with the
manufacturer’s instructions. ELISA plates contain anti-
gen that captures host anti-DENV NS1 antibodies spe-
cific to all four serotypes and include calibrators that
normalise optical density outputs to yield IgM and IgG
panbio units.
Data analysis
We categorised the dengue immune status (primary,
post-primary, historical and negative) of the surveyed
cases reports, using laboratory data, according to a pre-
viously developed algorithm [14]. Prior to categorisation,
we generated additional variables: IgG to IgM ratio (IgG
panbio units/IgM panbio units) and disease day (symp-
tom onset date—reporting date). We excluded those
under 6 months of age (0.4% 91/20,666) due to the po-
tential influence of maternal antibodies and individuals
who reported ≥6 days after symptom onset due to the al-
gorithm’s inability to categorise convalescent infections.
Details of the immune status algorithm are described in
Additional file 3. Briefly, suspected dengue patients were
categorised as active (PCR+ or IgM+) or non-active
(PCR- and IgM-) dengue infections. Active dengue infec-
tions were further categorised as primary or post-
primary (dengue infection with at least one previous fla-
vivirus infection). Non-active dengue was classified as
negative (anti-DENV IgG-) or historical (anti-DENV
IgG+) for dengue.
Across the Philippines, we investigated temporal pat-
terns in reported dengue immune status and serotype by
stratifying immune status (primary and post-primary)
among active dengue infections and dengue serotype
(DENV1-4) among those DENV PCR+ over 30-day in-
tervals. Among those reporting with primary and post-
primary infections, we explored age-stratified disease se-
verity patterns. Univariable logistic regression models
were used to calculate odds ratios of being severe op-
posed to non-severe (warning signs and no warning
signs) with the explanatory variables being age-stratified
primary or post-primary dengue immune status. Regres-
sion models were fit using the ‘Logit’ command in
STATA (v.16).
In each of the 13 sampled cities, we estimated all age
and age-stratified (under 5 years and 10 years) aggre-
gated annual dengue incidence rates among those who
reported and resided in the same city. To estimate the
average city population at risk of infection, we utilised
city-specific population data from the 2015 population
census (Philippine Statistics Authority) and population
growth rates calculated between 2010 and 2015 (Add-
itional file 2). City-specific population growth rates were
used to estimate the population in each of the non-
surveyed years. Average incidence per annum per 1000
persons equated to the number of case reports over the
persons years at risk (average population over the study
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period multiplied by 4 years) multiplied by 1000 (Add-
itional file 4).
In sampled cities, we estimated the average annual
FOI estimated over the study period among non-active
dengue infections (IgG+ historical and IgG-negative den-
gue cases). Seroprevalence corresponded to the propor-
tion of the non-active dengue cases who were IgG
seropositive to any serotype. Catalytic models were fit,
by maximum likelihood, to estimate age-seroprevalence
and derive seroconversion rates which correspond to the
average annual rate individuals seroconvert from IgG−
to IgG+ status; a rate analogous to the FOI. Under the
assumption, individuals remain IgG+ after seroconver-
sion and all circulating serotypes contributed equally to
transmission, a simple catalytic model (Eq. 1) calculates
the probability of being IgG seropositive at specific ages
(a) by fitting a constant force of infection parameter (λ)
by least squares:
P að Þ ¼ 1−e−λa  ð1Þ
Assuming IgG antibodies can wane over time to low
levels undetectable according to the commercial ELISA
kits, as previously shown in [17–19], a reversible cata-
lytic model (Eq. 2) additionally estimates a seroreversion
rate (the average annual rate individuals serorevert back
to IgG-status) by fitting an additional seroreversion par-
ameter (ρ), by least squares:
Fig. 1 Location of 13 study-participating cities across the three principle geographical divisions of the Philippines that routinely provided serum
samples between 2014 and 2018
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To determine which catalytic model, simple or revers-
ible, was most appropriate to estimate the FOI, we used
AIC (Akaike information criterion) to determine super-
ior model fits in each city. Catalytic models were fitted
using a rho-constrained/unconstrainted ‘revcat’ com-
mand in STATA (v.16).
We investigated whether routinely collected surveil-
lance metrics represent surrogate indicators of the FOI
at the city level, we explored their statistical association
with the city FOI aggregated over the study period.
Non-laboratory surveillance metrics investigated in-
cluded all age/under 5/under 10 average annual dengue
incidence, mean age of all reported case reports/case re-
ports with dengue warning signs/case reports with se-
vere dengue. Laboratory-derived surveillance metrics
included the mean age of laboratory-confirmed active
dengue infections/primary dengue infections/post-pri-
mary dengue infections. The strength of association be-
tween the city-aggregated FOI and averaged surveillance
metrics were assessed using Pearson’s correlation coeffi-
cient (ρ, p value). Among surveillance metrics that sig-
nificantly correlated with the FOI at the city level (ρ, p
value<0.05), exponential regression models were used to
generate predicted FOI estimates. Lrtests were adopted
to justify exponential over linear model fits (p value<
0.05). Models were fit using a non-linear ‘nl’ command
in STATA (v.16). FOI estimates were subsequently con-
verted to annual attack rates (AR) (Eq. 3) to determine
the proportion of the sampled population who became
exposed to dengue in each city per year:
AR ¼ 1−e− λð Þ ð3Þ
Results
Data description
Demographic characteristics of the sampled and collated
acute case reports across the Philippines are highlighted in
Table 1. Similar demographic patterns were observed
among both case report datasets. The majority of patients
were aged 6–15 years of age, reported 3–4 days after the
onset of symptoms and presented with warning signs of
dengue. Among the surveyed case reports with laboratory
data, we revealed 18% (3310/18,366) were primary infec-
tions, 62.9% (11,560/18,366) were post-primary infections,
12.5% (2297/18,366) were historical dengue infections and
6.5% (1199/18,366) were negative dengue infections.
Overall dengue immuno-epidemiological patterns be-
tween 2014 and 2018 revealed both primary and post-
primary dengue infections were mainly children and
young adults (Fig. 2A) and continuously reported to
health facilities during the study period (Fig. 2B). Among
PCR+ case reports, we revealed by 2017 and 2018,
DENV-3 replaced DENV-1/2 as the most dominant
serotype across the Philippines (Fig. 2C). Among those
with disclosed symptom data (72.7% 13,357/18366), we
observed similar clinical manifestations among primary
and post-primary infections (Fig. 2D), whereby younger
individuals tended to present with more dengue warning
signs or severe dengue (Fig. 2E & F). Despite this, post-
primary infections were slightly more likely to present
with severe disease compared to primary infections (OR
1.22 [95%CI 1.01–1.48] p value 0.039) (Fig. 2G). Among
young primary infections, we observed no age-stratified
severity trends: individuals over 2 years, yet younger
than 25 years, were statistically no more/less likely to
present with severe disease than those under 2 years
(Fig. 2H). In contrast, young children with post-primary
infections were more likely to present with severe dis-
ease compared to their elders. Compared to post-
Table 1 Study population demographics. Characteristics of
sampled and collated acute dengue case reports across the
Philippines. Excludes patients who reported more than 5 days
after symptom onset and those under the age of 6 months
Demographics Surveyed case reports Collated case reports
%n n %n n
Age (years)
<5 15.9 2920 17.1 80,046
6–15 45.6 8371 39.1 182,999
16–25 23.4 4299 24.8 116,062
26–40 9.3 1716 11.5 53,803
>41 5.8 1060 7.5 35,117
Sex
Female 47 8624 47.3 221,446
Male 53 9742 52.7 246,581
Disease day
<2 28.5 5233 31.8 148,933
3–4 58 10,652 54.6 255,352
5 13.5 2481 13.6 63,742
Symptoms
No warning signs 14.2 2617 16.5 77,006
Warning signs 53.4 9811 50.3 235,619
Severe dengue 5.1 929 4.0 18,506
Non-disclosed 27.3 5009 29.2 136,896
DENV immune status
Primary 18 3310 – –
Post-primary 62.9 11,560 – –
Historical 12.5 2297 – –
Negative 6.5 1199 – –
Total 100.0 18,366 100.0 468,027
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primary infections under 2 years, those over 12 years
were significantly less likely to present with severe dis-
ease (Fig. 2I).
City-level dengue transmission dynamics
Among 13 study-participating cities during the study
period, we observed variation in estimated crude and
age-stratified incidence rates. All-age incidence was
highest in Baguio (3.75 cases per annum per 1000
[95%CI 3.65–3.86]) and lowest in Valenzuela (0.49 cases
per annum per 1000 [95%CI 0.46–0.52]). After stratify-
ing among younger age groups, city incidence rates
changed. The highest incidence rate among those under
ten was observed in Surigao (7.17 cases per annum per
Fig. 2 Immuno-epidemiological characteristics of dengue infections reporting across the Philippines between 2014 and 2018. A Age distribution
of the primary and post-primary dengue infections. B Temporal patterns in reporting primary and post-primary dengue infections. C Temporal
patterns in reporting DENV serotypes among active dengue infections. D Clinical manifestations of the primary and post-primary dengue
infections. E Age-stratified clinical manifestations of primary dengue infections. F Age-stratified clinical manifestations of post-primary dengue
infections. G Odds ratio [95% CI] for post-primary dengue infections to present with severe disease compared to primary dengue infections. H
Odds ratios [95% CI] for primary dengue infections to present with severe disease by age in years compared to those under 2 years. I Odds ratios
[95% CI] for post-primary dengue infections to present with severe disease by age in years compared to those under 2 years. 1° primary dengue
infections. 2° Post-primary dengue infections
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1000 [95%CI 6.71–7.65]) while the lowest rate was again
in Valenzuela (0.84 cases per annum per 1000 [95%CI
0.76–0.93]) (Additional file 4).
Across cities, we revealed prominent spatio-temporal
heterogeneity in serotype dominance (Fig. 3A) and im-
mune status reporting (primary/post-primary) (Add-
itional file 5). During 2015/16, cities in northern Luzon
were mainly burdened by DENV-1/2, yet by 2017 and
2018, DENV-3 had become the most dominant. In con-
trast, cities in Mindanao were burdened with DENV-3
throughout the entire study period, and in Surigao,
DENV-2 replaced DENV-3 as the most dominant sero-
type in 2016. It should be noted that for nearly every
year among all sampled cities, all four serotypes of den-
gue were detected among reporting PCR+ patients. Re-
garding the immune status of the population, patients in
the cities of southern Mindanao (Zamboanga, Cotabato
and Davao) had a higher probability of reporting as
post-primary opposed to primary dengue infections
compared to those in cities of Luzon. Within cities, we
observed temporal variation in immune status reporting.
For instance, in Valenzuela (Metro Manila), primary
dengue reporting significantly increased during 2016,
while in Tuguegarao, fell between 2015 and 2018.
Furthermore, we estimated the average annual dengue
FOI among the 13 cities aggregated over the study
period. In all cities, the reversible, opposed to the simple,
catalytic model produced superior model fits (reversible
model AIC < simple model AIC) (Additional file 6). We
therefore opted to estimate the FOI (or SCR) in each city
using the more complex, reversible model. Between each
city, the FOI rate ranged from 0.054 [95%CI 0.036-
0.081] per year in Baguio city to 0.249 [95%CI 0.223–
0.279] per year in Quezon city demonstrating spatial
heterogeneity in the transmission intensity (Fig. 3B).
Estimating the city-level FOI from routinely collected
surveillance metrics
To assess whether data from routine dengue case sur-
veillance activities could be used to estimate the FOI in
cities, we explored statistical associations between cata-
lytic model estimated city-level FOI against age/age-
stratified incidence and the mean age of different types
of dengue infections (Fig. 4). We observed a negative
correlation between the FOI and all-age average annual
incidence, whereby incidence increased with decreasing
FOI (ρ −0.692, p value 0.009). No association was identi-
fied between the city-level FOI and average annual age-
stratified (under 5 and under 10 years) incidence rates
(ρ, p value>0.05). Among all those who reported sus-
pected dengue, we identified a negative correlation be-
tween the FOI and the mean age of all case reports (ρ
−0.639, p value 0.019). For those who reported with den-
gue warning signs, we identified a similar association
where the decreasing FOI correlated with the increasing
mean age (ρ −0.642, p value: 0.018). In contrast, we ob-
served a weak association between the FOI and the
mean age of severe case reports (ρ −0.497, p value
0.059). Among those with laboratory-confirmed dengue
infections, we identified stronger associations between
mean age and the FOI. The mean age of active dengue
infections (primary and post-primary) increased with de-
creasing FOI (ρ:–0.749, p value 0.003). An association
that was strengthened after stratifying among only pri-
mary infections (ρ −0.848, p value<0.001), yet remained
similar when stratifying by post-primary infections (ρ
−0.719, p value 0.006). We repeated these associations
using FOI estimates generated from simple, opposed to
reversible, catalytic models and still found the mean age
of primary infections had the strongest association with
the FOI (ρ −0.720, p value 0.005) (Additional file 7).
For each surveillance metric that demonstrated a sta-
tistically significant association with the FOI, we esti-
mated the predicted FOI using exponential regression
models where appropriate (ρ, p value<0.05). For each
statistically associated metric, except incidence, exponen-
tial opposed to linear model fits were favoured (Lrtest, p
value<0.05). Using these regression models, we estimated
annual dengue attack rates from predicted FOI estimates
from the most associated laboratory- and non-laboratory-
derived metrics: the mean age of laboratory-confirmed
primary dengue infections (Table 2) (Additional file 8)
and the mean age of case reports with warning signs
(Additional file 9). Annual trends in the mean primary
age, and thus predicted attacks rates, revealed spatio-
temporal heterogeneity in dengue transmission intensity
among sampled cities. In Zamboanga city, the attack rate
(AR) increased dramatically from 4% [95%CI 4–4%] of the
population being exposed in 2014 to 30% [95%CI 19–
46%] in 2018. In Manila city, the AR decreased during the
study period from 27% [95%CI 20–36%] in 2015 to 10%
[95%CI 8–14%] in 2018. In Quezon city, the AR remained
high between 17% and 23% during the entire study period
which is consistent with the estimated FOI according to
the catalytic model (AR 22% [95%CI 20–24%]). For some
cities (Davao, Naga), a change in serotype dominance cor-
responded with increase in AR; however, this was not ob-
served in others (Tuguegarao, Manila). We also predicted
the annual ARs according to the mean age of case reports
with warning signs that also highlighted spatio-temporal
heterogeneity in FOI, yet was less consistent with the
overall AR according to the catalytic model (Additional
file 10).
Discussion
We explored methods to routinely describe dengue
transmission intensity among cities across the
Philippines. Using data from surveillance operations, we
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Fig. 3 City-level immuno-epidemiological characteristics of the reporting dengue population between 2014 and 2018. A The percentage of PCR-
positive patients who are DENV-1/2/3/4-positive. Shading: 95% CIs. B The dengue FOI in 13 cities across the Philippines aggregated between
2014 and 2018. FOI corresponds to the average annual seroconversion rate calculated among non-active dengue cases (historical and negative
dengue cases). Black dots: observed age-seroprevalence. Red lines: fitted age-seroprevalence with 95%CIs (red dash)
Fig. 4 The city and study period aggregated association between the average annual FOI and surveillance metrics. A Crude incidence. B Under
five incidence. C Under 10 incidence. D Mean age of case reports. E Mean age of case reports with warning signs. F Mean age of case reports
with severe dengue. G Mean age of active infections. H Mean age of primary dengue infections. I Mean age of post-primary dengue infections. ρ
Pearson’s R. A–F Data from passive surveillance. G–I Data from laboratory surveillance. Red dash: predicted FOI according to regression models
for metrics with statistically significant associations with FOI (ρ, p value>0.05). Linear regression models were favoured for crude incidence while
exponential regression models had superior model fits for mean case report age, case report with warning signs age, active DENV age, primary
DENV age and post-primary DENV age (Lrtest, p value<0.05). X refers to the annual mean surveillance metric
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found the mean age of laboratory-confirmed primary
dengue infections and the mean age of case reports with
warnings signs, to a lesser extent, represented suitable
surrogate indicators of the FOI. Both these easily com-
puted metrics correlated better than crude and age-
stratified incidence with the FOI estimated from sero-
prevalence data. Our results highlight prominent spatio-
temporal heterogeneity in dengue serotype dominance
and reported immune status and the FOI across urban
centres in the Philippines.
It is well documented that secondary, opposed to pri-
mary, dengue infections are at a greater risk of develop-
ing severe disease [20–22], yet we found those
categorised as post-primary infections were only slightly
more likely to present with severe disease than primary
infections. This made us suspect that some of those clas-
sified as post-primary were tertiary and quaternary den-
gue infections, given these types of infections are
thought to be less severe than secondary infections, al-
though it is still widely assumed post-secondary infec-
tions are often asymptomatic [2, 23]. Furthermore, we
identified all four serotypes of dengue in every city al-
most every year making it plausible for individuals resid-
ing in urban centres to suffer multiple dengue infections
over their lifetime. Lastly, we found that younger, op-
posed to older, post-primary dengue infections were at
greater risk of presenting with severe disease. A trend
possibly attributed to younger and older post-primary
infections representing secondary and post-secondary in-
fections, respectively, as shown in [2], although this may
also be attributable to a different disease presentation in
older people.
Our city FOI estimates, aggregated over 5 years and
generated from catalytic models, were comparable to a
2016 estimate in Cebu (central Philippines) [23] and re-
vealed a long-term spatial heterogeneity in dengue trans-
mission intensity, similarly shown in China [24] and
Colombia [25]. We found catalytic models fit with sero-
reversion parameters resulted in superior model fits des-
pite sero-reversion being very low across sampled cities.
This is consistent with previous findings that docu-
mented a minority of dengue cases, who were likely ex-
posed once, experienced IgG waning [17, 18]. To
determine whether the FOI could be estimated from
data routinely collected by dengue surveillance opera-
tions, we explored the association between FOI, esti-
mated from catalytic models, against various dengue
surveillance metrics. Surprisingly, aggregated at the city
level and over the study period, all-age reported inci-
dence was higher in lower FOI areas. This trend how-
ever has previously been reported in Singapore [26] and
was thought to be attributed to an age shift in disease
burden. In low transmission areas, individuals are more
likely to experience a dengue infection at a later stage in
their life when they may have heightened individual dis-
ease awareness and possibly easier access to care. Conse-
quently, low transmission areas may experience
increased case reporting. In addition, this trend could
also be explained by reduced health-seeking behaviour
in high FOI cities wherein individuals refrain from
Table 2 The annual predicted dengue attack rates among sampled cities between 2014 and 2018 according to the mean age of
laboratory confirmed primary dengue infections. 95%CIs correspond to the upper and lower 95%CIs of the annual mean age of
primary infections. Attack rates according to catalytic models were derived from FOI estimates from reversible catalytic models
#Attack rate (AR): 1-exp(-FOI)
aEstimated annual attack rate according to the FOI derived from the mean primary DENV age (FOI=0.041+1.329×0.797×), where x equals the annual mean primary
dengue age
bEstimated annual attack rate according to the FOI derived from the reversible catalytic model, Eq. 2, where FOI equals λ
Attack rate
0.25-0.30 0.20-0.25 0.15-0.20 0.10-0.15 0.05-0.10 0.05-0.10
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reporting with symptoms as they are aware of many
others with this often mild, self-limiting disease. In con-
trast in low FOI areas, individuals may be more
prompted to seek care as they less familiar with the dis-
ease and are more concerned by unfamiliar symptoms.
However, future population KAP (knowledge attitudes
and practises) surveys in high- and low-transmission set-
tings would be valuable in better describing these
health-seeking patterns. Finally, this disparity could par-
tially be explained by the FOI and incidence being mea-
sures of infection and disease, respectively. FOI
estimates also include those asymptomatic with dengue
who are thought to account for approximately 75% of all
dengue cases and would unlikely seek treatment [27].
More surprisingly however, after stratifying incidence by
age, we observed no association with the FOI which con-
tradicts findings in [9]. We speculate that variable
healthcare access and reporting across the country may
account for this irregularity and remains an area of con-
tinued investigation. Together, these findings suggest
that simply allocating control interventions to areas with
elevated reported incidence might exclude regions with
higher burdens of infection.
In cities, we found that the average age of reported
dengue infections with clinical dengue outcomes in-
creased with decreasing aggregated transmission inten-
sity. Interestingly, the mean age of those reporting with
just warning signs of dengue, opposed to severe dengue,
proved a superior indicator of FOI. The poor specificity
dengue clinical diagnosis is well documented as other fe-
brile infections can present with similar disease manifes-
tations [28–30]. Yet, compared to warning signs, severe
disease is a far rarer outcome, particularly among pri-
mary and older post-primary infections. Moreover, in
Thailand, reported severe dengue manifestations have
been shown to be highly spatially and temporally
heterogenous due to climactic factors [31]. Together,
these factors likely account for the lack of association
between FOI and age of case reports with severe disease.
In contrast to the age of clinically diagnosed dengue
patients, the age of laboratory-confirmed dengue cases
had a stronger association with the FOI, likely a conse-
quence of excluding other co-endemic febrile infections.
Yet, among laboratory confirmed infections, the age of
those reporting with primary, rather than post-primary,
infections proved a better indicator of FOI. We propose
two main factors account for this difference. Age pat-
terns of reporting post-primary infections might be in-
fluenced by spatio-temporal imbalances in immune
status reporting, observed in this study and previously in
Vietnam [32] and Taiwan [33]. In high transmission set-
tings, where a higher proportion of the post-primary
reporting population include tertiary/quaternary infec-
tions, the mean age would be higher than an equally
high transmission setting where most of the post-
primary infections were secondary infections. In con-
trast, the age of reported primary infections remains un-
affected by imbalances in immune status reporting.
Secondly, studies have shown that Zika, a structurally
homologous virus to dengue, elicits cross-reactive IgG
that primes individuals for secondary dengue infections
[34, 35]. Therefore, spatio-temporal imbalances in po-
tential Zika transmission across the Philippines may
similarly impact the age of post-primary, yet not pri-
mary, dengue infection reporting. These interactions led
us to propose the age at which individuals report with
their first dengue infection is the better surrogate of
transmission intensity which we used to estimate annual
FOI across cities. It should be noted however, given that
individuals are classified as primary or post-primary ac-
cording to antibody titre and ratio thresholds, a minority
of the study population with metrics on the cusp of
these cut offs may have been misclassified [14].
Upon estimating city level, annual dengue attack rates
according to the age of primary dengue infections, we
demonstrated that yearly estimates correlated with over-
all attack rates according to the catalytic model. Patterns
in predicted annual attack rates across cities revealed
changing patterns in transmission intensity over time, as
seen in Singapore [26]. We identified cities where trans-
mission is stable, emerging and decreasing. Information
that is critical for national dengue surveillance opera-
tions to plan for the future [36]. In Zamboanga, despite
a relatively low overall FOI, annual predicted attack rates
revealed that transmission intensity increased during the
study period, a trend undetected in the collated inci-
dence data. Zamboanga could therefore be earmarked
for heightened surveillance activities to better character-
ise worrying predicted trends in the burden of infection.
In Naga, we identified a jump in FOI coinciding with a
switch in serotype dominance, yet this was unobserved
in other cities. Approximating transmission intensity
from the age of reported primary dengue infections has
two major benefits. Firstly, existing surveillance opera-
tions can generate attack rates quickly and simply.
Moreover, as a consequence of the exponential relation-
ship, slight changes in the age of reported primary infec-
tions correspond to larger changes in transmission
intensity. This enables FOI estimates to be generated at
more granular temporal scales, which are more inform-
ative than long-term estimates derived from catalytic
models. As well as describing dengue transmission in-
tensity patterns, we speculate monitoring age patterns of
reported primary cases could assist in dengue vaccine
deployment. Currently, the only licenced dengue vac-
cine, Dengvaxia®, is recommended for individuals aged
between 9 and 45 years in endemic areas, presumably as
these likely include those with prior dengue exposure
Biggs et al. BMC Medicine          (2021) 19:217 Page 11 of 14
[37]. Our results highlight the spatio-temporal hetero-
geneity in the age patterns of those reporting with their
first infection; therefore, monitoring the age of these in-
fections could potentially help identify suitable age
ranges in specific locations to receive vaccination, al-
though individual pre-vaccination testing would still be
necessary and this requires legislative changes.
There are limitations associated with these findings.
FOI estimates were generated from reporting, non-
active, dengue infections with/without previous dengue
IgG exposure. Consequently, we may have oversampled
individuals who were more prompted to seek health care
if they experienced a prior dengue infection. Yet, only
25% of dengue infections are thought to experience
symptoms that would prompt them to seek care [27],
and we concluded this health-seeking bias was minimal.
Secondly, our fitted catalytic model assumes serotypes
contributed equally to transmission over time. Still,
given we identified every serotype in each city and that
serotype dominancy changed rapidly over the 5-year
sampling period, it is reasonable to assume that over the
previous decades, from which the FOI is estimated, peri-
odic serotype dominancy may have resulted in serotypes
contributing equally to overall transmission. Lastly, our
analysis confirms the age of primary dengue infections is
associated with FOI at the city level, yet it remains un-
confirmed as to whether the age of reported dengue
cases accurately represent transmission intensity at
lower administrative levels where patients are more
likely to cross administrative borders for care. Similarly,
our analysis focused on revealing annual trends in den-
gue transmission intensity. It remains unknown whether
seasonal biases may influence the reporting age of pri-
mary dengue infections at more granular temporal
scales.
Conclusion
We described methods for estimating city-level dengue
transmission intensity using metrics obtained from both
national laboratory and non-laboratory dengue surveil-
lance operations. We revealed the mean age of those
reporting with primary dengue infections correlated best
with the FOI using laboratory data, while the mean age
of those reporting with clinically diagnosed warning
signs represented the best surrogate of FOI using non-
laboratory surveillance data. Our work highlights the im-
portance of laboratory dengue surveillance operations
and provides a framework for other dengue-endemic
countries to better characterise dengue transmission pat-
terns and combat the global threat of this disease.
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